Navigation Links
Avicena Reports Second Quarter 2007 Results
Date:8/31/2007

ng and marketing expenses were $360,741 for the three month period ended June 30, 2007, an increase of 33% from $271,246 for the corresponding 2006 period.

General and administrative expenses of $1,248,605 for the second quarter of 2007 were up from $628,366 in the prior year period, primarily based on non-cash stock based compensation expense from options issued in April of 2007, and estimated accrued expenses associated with the delay in filing registration statements from previous preferred offerings

RECENT CORPORATE ACHIEVEMENTS:

Avicena announced plans for a confirmatory Phase III Amyotrophic Lateral Sclerosis (ALS) trial after meeting with the Food and Drug Administration (FDA). The confirmatory Phase III trial of the drug candidate, AL-02, for the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease), follows two completed studies demonstrating a positive trend towards increased survival.

Avicena announced patient enrollment on target in National Institutes of Health (NIH) Phase III Parkinson's Disease Trial. The Phase III trial, sponsored by the NIH's National Institute of Neurological Disorders and Stroke (NINDS), is designed to evaluate the potential of Avicena's lead Parkinson's disease drug candidate, PD-02, in slowing disease progression. This trial will enroll over 1,720 patients and is one of the largest Parkinson's disease trials ever conducted.

Avicena announced advancement of Huntington's disease clinical program into Phase III in early 2008. Based on a dose-ranging study, Avicena selected an optimal dose of its novel drug candidate HD-02 for the treatment of Huntington's disease. The Company plans to initiate a Phase III trial in early 2008.

ABOUT AVICENA

Avicena Group, Inc. is a Palo Alto, California-based late stage biotechnology company that develops central nervous system therapeutics for neurodegenerative diseases. The company's core technologies, supported by a robust intellectual
'/>"/>

SOURCE Avicena Group, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... 01, 2014 Chantel Lee ’15 and Eli ... 10 40-hour weeks with Dr. Juan Rodriguez, Professor of Physics, ... a common diabetic eye disease caused by changes in the ... and Eli accomplished is quite remarkable,” said Rodriguez. “They took ... when they started, and together carried it to near completion ...
(Date:8/1/2014)... CHICAGO , Aug. 1. 2014 As ... U.S., the 2014 AACC Annual Meeting & Clinical Lab ... testing and patient care are introduced to the healthcare ... by the Expo,s 650 exhibitors will include the latest ... Advances in smartphones and biosensors have enabled ...
(Date:8/1/2014)... Research and Markets has announced ... (SNP) Genotyping and Analysis Market 2014-2018" report to ... Single Nucleotide Polymorphism (SNP) genotyping is the ... the genome of various species. SNPs are commonly present ... technology can analyze thousands of SNPs and has the ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 Testing ... led to a better understanding embryonic development. ... reorganize into structurally and functionally distinct tissues is ... defects. Prof. Todd McDevitt, Melissa Kinney, and ... signals interact with biochemical cues to control many ...
Breaking Biology Technology:Two Centenary College Students Tackle Diabetic Retinopathy Research 2Lab-on-a-Chip Technology to Be Featured at 2014 AACC Annual Meeting & Clinical Lab Expo 2Lab-on-a-Chip Technology to Be Featured at 2014 AACC Annual Meeting & Clinical Lab Expo 3Global Single Nucleotide Polymorphism (SNP) Genotyping and Analysis Market 2014-2018 2Study Links Biomechanics and Gene Expression in Stem Cells 2
... 28 Pharmacopeia,(Nasdaq: PCOP ), an innovator ... therapeutics, today announced advancements for two members,of its ... and,Regulatory Affairs, has been promoted to Senior Vice ... S. David Kimball, Ph.D., Senior,Vice President, Chemistry and ...
... DIEGO, Feb. 28 Anadys Pharmaceuticals,Inc. (Nasdaq: ANDS ... a,Phase I study of ANA773, the company,s oral TLR7 ... trial is a safety,and tolerability study designed to identify ... to select the dose and,schedule for Phase II trials., ...
... report in the February 28, 2008, New England Journal ... Newborn Screening Program (NENSP) of the University of Massachusetts ... genetic disease, providing what may be the first demonstration ... , The state of Massachusetts has offered universal ...
Cached Biology Technology:Pharmacopeia Announces Management Team Changes 2Pharmacopeia Announces Management Team Changes 3Pharmacopeia Announces Management Team Changes 4Pharmacopeia Announces Management Team Changes 5Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients 2Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients 3Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients 4Data show a decline in cystic fibrosis since introduction of prenatal carrier screening 2
(Date:7/31/2014)... beneath many of the roughly 156,000 gas stations ... corrosion in parts of underground gas storage tankscorrosion ... of groundwater, a source of drinking water. In ... reported many rapidly corroding gas storage tank components ... associated with use of gasoline-ethanol blends and the ...
(Date:7/31/2014)... models against the highly infectious and virulent bacterium, ... kills approximately 30,000 Americans annually. The research is published ... , In the study, the vaccine protected the ... by C. difficile , as well as from ... the human disease, after only two immunizations. , ...
(Date:7/31/2014)... has been made to help better identify and treat those ... narrowing and enlarging of medium sized arteries in the body, ... organs causing damage. In a new report appearing in August ... scientists provide evidence that that FMD may not be limited ... a connection to abnormalities of bones and joints, as well ...
Breaking Biology News(10 mins):NIST corrosion lab tests suggest need for underground gas tank retrofits 2C. difficile vaccine proves safe, 100 percent effective in animal models 2Scientists discover biochemical mechanisms contributing to fibromuscular dysplasia 2
... and 17 September, in the context of France,s presidency ... GMES 2008, at the Grand Palais. The GMES ... set up to provide services relating to the environment, ... services draw on data - mainly Earth observation data ...
... for oceanic vessels has been impeded by worldwide concerns ... gas emissions that impact the Earth,s climate. A ... examines "Emission Tradeoffs among Alternative Marine Fuels: Total Fuel ... Marine Diesel Oil," in a recent issue of ...
... The 2009 Force Protection Equipment,Demonstration (FPED VII) ... VA, and Marine Corps Base, Quantico, VA, next ... Global War on Terror., The demonstration is ... of commercial off-the-shelf equipment solutions to current,and evolving ...
Cached Biology News:Major European program for the environment under the spotlight in Lille, France 2Fuel emissions from marine vessels remain a global concern 22009 Force Protection Equipment Demonstration Set for Next May 19-21 2
... Acridinium NHS ester can ... and nucleic acids. The covalently ... produce chemiluminescence in the presence ... ester-labeled proteins can be used ...
... 2-color real-time PCR detection system holds 48 x ... array of 48 LEDs independently excites fluorescence (470-500 ... filtered photodiodes detects emitted light (523-543 nm and ... MJ Mini cycler, whose Peltier heat pumps provide ...
... flow cytometry accessible to anyone in the lab. ... addition to Guavas on-demand microcapillary flow cytometry systems ... use, surprisingly affordable, very compact, and nicely equipped ... Guava EasyCyte Mini has all of the functionality ...
... hold up to 6 strain chambers with precise ... use design ensures that cells grow over long ... compression. This unit allows you to control the ... 64 unique strain settings. The instrument fits in ...
Biology Products: